Belgian scientists at the UCL (Université Catholique de Louvain) and the Wageningen University have made 'ground-breaking discoveries' in the fight against obesity and diabetes type 2. Using two separate treatments with the Akkermansia bacterium, they managed to halt the development of both diseases in mice.
If the tests prove to work effectively for humans as well, then "these people, as the first in the world, are paving the way to the production of a future medicine". This will not only aid in the fight against diabetes and obesity, but also against cardiovascular diseases and inflammations of the intestines. So says the UCL. The study was already published in 'Nature Medicine'.
Patrice Cani (UCL) and Willem Vos (Wageningen) discovered that when the Akkermansia is used alive, after being pasteurised at 70° C, it can be used to halt the development of both disease in mice. In tests it was shown that pasteurisation does not only double the effect of the bacteria, but it also made it possible to correct the disease and, as a world's first, prevent it. Pasteurised Akkermansia is easier to store and can more easily be administered to humans.
Since the end of last year, the academic hospital of the UCL is conducting a clinical research, although this is only in its primary phase. The scientists hope to be able to prove the positive tests seen in mice in humans as well.
About ten years ago, the UCL scientists were the first to prove that the bacterium plays a decisive role in the fight against obesity and diabetes type 2.